M N Choudhry1, H Soran, H M Ziglam. 1. Department of Musculoskeletal Medicine, Platt Rehab II, Purple zone, Manchester, M13 9WL, UK.
Abstract
BACKGROUND: Clostridium difficile is the most common infectious cause of colitis and has been increasingly diagnosed in hospitalized patients. The number of prescriptions for proton pump inhibitors (PPIs) has also increased significantly over time. Few studies have reported an association between C. difficile-associated disease (CDAD) and PPI use. AIM: To assess the extent and appropriateness of PPI prescribing in patients diagnosed with C. difficile infection. METHODS: We prospectively studied PPI prescriptions in 138 hospitalized patients diagnosed with C. difficile infection over a 4-month period. Clostridium difficile infections were diagnosed by the presence of C. difficile toxin in the stools. The appropriateness of prescriptions and relevant investigations were assessed by interview of patients and review of patient records. RESULTS: Sixty-four percent (88 of 138) of all patients who developed C. difficile infections were on PPIs. A valid indication for PPIs therapy was not apparent in 63% of the patients. CONCLUSION: There appears to be a widespread and inappropriate use of PPIs in hospital practice. Reduction of unnecessary PPIs use may be an additional strategy to reduce the incidence of this infection.
BACKGROUND:Clostridium difficile is the most common infectious cause of colitis and has been increasingly diagnosed in hospitalized patients. The number of prescriptions for proton pump inhibitors (PPIs) has also increased significantly over time. Few studies have reported an association between C. difficile-associated disease (CDAD) and PPI use. AIM: To assess the extent and appropriateness of PPI prescribing in patients diagnosed with C. difficileinfection. METHODS: We prospectively studied PPI prescriptions in 138 hospitalized patients diagnosed with C. difficileinfection over a 4-month period. Clostridium difficile infections were diagnosed by the presence of C. difficile toxin in the stools. The appropriateness of prescriptions and relevant investigations were assessed by interview of patients and review of patient records. RESULTS: Sixty-four percent (88 of 138) of all patients who developed C. difficile infections were on PPIs. A valid indication for PPIs therapy was not apparent in 63% of the patients. CONCLUSION: There appears to be a widespread and inappropriate use of PPIs in hospital practice. Reduction of unnecessary PPIs use may be an additional strategy to reduce the incidence of this infection.
Authors: Orlaith B Kelly; Catherine Dillane; Stephen E Patchett; Gavin C Harewood; Frank E Murray Journal: Dig Dis Sci Date: 2015-04-04 Impact factor: 3.199
Authors: Hojjat Salmasian; Daniel E Freedberg; Julian A Abrams; Carol Friedman Journal: Pharmacoepidemiol Drug Saf Date: 2012-12-12 Impact factor: 2.890
Authors: Tony Antoniou; Erin M Macdonald; Simon Hollands; Tara Gomes; Muhammad M Mamdani; Amit X Garg; J Michael Paterson; David N Juurlink Journal: CMAJ Open Date: 2015-04-02
Authors: David A Kleiman; Toni Beninato; Brian P Bosworth; Laurent Brunaud; Thomas Ciecierega; Carl V Crawford; Brian G Turner; Thomas J Fahey; Rasa Zarnegar Journal: J Gastrointest Surg Date: 2013-11-09 Impact factor: 3.452